Eqis Capital Management Inc. increased its stake in Opko Health, Inc. (NASDAQ:OPK) by 16.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 39,781 shares of the biotechnology company’s stock after buying an additional 5,622 shares during the period. Eqis Capital Management Inc.’s holdings in Opko Health were worth $262,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in OPK. Russell Investments Group Ltd. bought a new stake in shares of Opko Health during the fourth quarter valued at about $648,000. Comerica Bank bought a new stake in shares of Opko Health during the fourth quarter valued at about $117,000. Dimensional Fund Advisors LP boosted its position in Opko Health by 2.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,589,903 shares of the biotechnology company’s stock valued at $14,811,000 after buying an additional 30,851 shares in the last quarter. Envestnet Asset Management Inc. boosted its position in Opko Health by 23.6% in the fourth quarter. Envestnet Asset Management Inc. now owns 15,355 shares of the biotechnology company’s stock valued at $142,000 after buying an additional 2,927 shares in the last quarter. Finally, AQR Capital Management LLC acquired a new position in Opko Health during the fourth quarter valued at $105,000. Institutional investors and hedge funds own 23.05% of the company’s stock.

Shares of Opko Health, Inc. (NASDAQ OPK) traded up 1.94% on Monday, hitting $6.32. The stock had a trading volume of 3,367,104 shares. The stock’s market cap is $3.54 billion. Opko Health, Inc. has a 12 month low of $5.99 and a 12 month high of $12.15. The stock has a 50 day moving average of $6.48 and a 200-day moving average of $7.40.

Opko Health (NASDAQ:OPK) last released its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by $0.02. The company had revenue of $296.10 million for the quarter, compared to analysts’ expectations of $313.36 million. Opko Health had a negative net margin of 3.60% and a negative return on equity of 2.13%. Opko Health’s revenue for the quarter was up 1.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.02) earnings per share. Equities research analysts anticipate that Opko Health, Inc. will post ($0.20) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/07/eqis-capital-management-inc-increases-position-in-opko-health-inc-opk-updated.html.

Several research firms have weighed in on OPK. BidaskClub cut Opko Health from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Jefferies Group LLC reissued a “hold” rating and issued a $8.00 price objective on shares of Opko Health in a research report on Thursday, July 27th. Zacks Investment Research raised Opko Health from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Barrington Research boosted their price objective on Opko Health to $11.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 18th. Finally, Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $19.50 price objective on shares of Opko Health in a research report on Tuesday, June 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $14.72.

In other Opko Health news, CEO Phillip Md Et Al Frost acquired 1,125,000 shares of the stock in a transaction dated Wednesday, May 10th. The shares were acquired at an average cost of $6.96 per share, for a total transaction of $7,830,000.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at $21,359,898.96. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Vice Chairman Jane Ph D. Hsiao acquired 40,000 shares of the stock in a transaction dated Wednesday, May 10th. The stock was acquired at an average price of $6.97 per share, for a total transaction of $278,800.00. Following the completion of the transaction, the insider now directly owns 24,723,133 shares of the company’s stock, valued at $172,320,237.01. The disclosure for this purchase can be found here. Insiders have purchased 2,756,000 shares of company stock worth $18,268,617 over the last quarter. 40.19% of the stock is owned by company insiders.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Institutional Ownership by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.